%PDF-1.6
%
1 0 obj
<< /Lang (de) /MarkInfo << /Marked true >> /Metadata 3 0 R /Outlines 5 0 R /PageLayout /OneColumn /PageMode /UseOutlines /Pages 71 0 R /StructTreeRoot 73 0 R /Type /Catalog >>
endobj
2 0 obj
<< /Author (Pfizer-Pharma GmbH) /Company (Pfizer Inc) /CreationDate (D:20120509153959+02'00') /Creator (Acrobat PDFMaker 10.1 fr Word) /ModDate (D:20120509154211+02'00') /Producer (Adobe PDF Library 10.0) /SourceModified (D:20120509101226) /Subject (Gebrauchsinformationen) /Title (Gevilon 600 mg; 900 mg Filmtabletten) >>
endobj
3 0 obj
<< /Subtype /XML /Type /Metadata /Length 4220 >>
stream
2012-05-09T15:42:11+02:00
2012-05-09T15:39:59+02:00
2012-05-09T15:42:11+02:00
Acrobat PDFMaker 10.1 für Word
uuid:c39df586-3df3-47a1-93ea-73b8f2d6eeec
uuid:3ca45779-73db-42e5-805b-f67cde43a700
4
application/pdf
Gevilon 600 mg; 900 mg Filmtabletten
Pfizer-Pharma GmbH
Gebrauchsinformationen
Adobe PDF Library 10.0
D:20120509101226
Pfizer Inc
endstream
endobj
4 0 obj
<< /Type /ObjStm /Length 1570 /Filter /FlateDecode /N 65 /First 500 >>
stream
xXnF+2& :n5b7#]P$LQI٭6CV^3IQD̽)JH2deRc$IsNL)1Ii7EL$ #qR
8%8q, &!QVCNI2
Gݺ;a28BrlI2 %?r*8@ %%DjE4Pe$!ʤX!)$- I $D ?YyUem[z? !Dlߝkp7'>?]eɡ]4hbݬ\қohikگolG(Dod^tv݁~?U=;yПwB{ӵ=2-|Ǔ Yҡ.+0<":ڛ@Ώ lU<20qD JR ;faoN##b19X|j֗SC%@꼰td)M}B .i*ϋ1r:(\tjDyqc1+2H4eA&IaٲsfT ԃo:y&vƖj7fT|&Ky)CZ8hnrT[[H%12#H}!fdn] [uPus=bX5ly~~`䡻9xFXݷ0GvvFm9 |(JysAF
1@Hg>OfR`wX`b+D}%xemޞepd~H;7k^KBa_iP̣-e*#Tʢo3(P>ʪo53NIt<5L~16Ɍ~eݴy+D
f褃mW;B>L||:j&7;5-?(0F!L@q1u h-rd`,`L
XNh bjSBC=O㰷nWw_~ihQ},QVtzf+Kc0[8 6>CpbaQquÓWr`ʂQv"alԿN$J!p散G?O12&7_`3q>L۹*l*4[ GpOB,ꪩO<٨'6yƷp9.r\o+1x_jB<2WƴT1w5zLmia|}Sy=8?]Gzg$aF4HեWN:5xb,1Y[rfpLV.U/*t
-/3endstream
endobj
70 0 obj
<< /Type /ObjStm /Length 76 /Filter /FlateDecode /N 1 /First 5 >>
stream
x37T0ಱQw/+Q0WL)VV00P0PR047ҦPJCi(m cC*RS >endstream
endobj
72 0 obj
<< /Type /ObjStm /Length 1812 /Filter /FlateDecode /N 100 /First 868 >>
stream
xYێF}WlWW_%) A@"60U`f5Jw;R""zjOW.oa]EW#Jي+QJuJs!ErջPJ)DWVbH{t1$.&N 1j)Cq͋5rZE
_ivMj)|͋E
_[sE9XAQ,RI8b WY`ab))*aNr)0e!I$YI20e&a.,^Ne 0HXGAĉ.,#_Kb\*rP"Wudut!q s0,0W IR&G(-F[UI5YM5bj& {& #% FS Y5VHf3s樱HjY/aܣ,Im,Ym6)͚Em6KUGb\iT )%Yͽ{wųnzyTOwNOv]qw?]^k9wxz>?No) ((%L$ ɐr& 7n*O'\_p}>\.O>vg؝WF>j/WH=O߱O `.'i܇a7nݜG;v3%@2d|||?WՑn%CF!$U˰a.]Wb#y+F^1W|8
'\p]u/Nc87Ӯ=HB7\O?M#^B G;(|=J1F\q!ąx:QGsG!ڸMwi#KYFZ
{=^{Q#+wpBvoӛyZ>"tS58CtP١^Mt갗m/]
sPwn:sڳ;)NPۇIodӍvgs@mz!jv[gCmZ_nnsNB:7jzZ$|H3C"vEׁ8/:מB"Eac۸p~uwo-/jj@.ELOasyQOOfscċ~ =5lw&^7ejcw``w`}jڧ)}jڧ}wbyJ))E_Fÿn|?;#B``V:=RZ1u:#AXPg0393[#~xy>E [Ą-aḃ=0qxظel\g0cE_ȣZ"FF11ju$dY"FBgΈpgpg@3 [$~WvxKq 3.a%̸0f\Kl ,av%0FT`JG o///j3>
stream
xݔJ@>?*\{?pra(:}5֏jѓ716@L 9S~' "ؤIӝ~(p":j'rJҨz_]r Gendstream
endobj
181 0 obj
<< /Type /ObjStm /Length 1013 /Filter /FlateDecode /N 100 /First 872 >>
stream
xXˮ4tu%X ,,w4OU $'EJ%T&`sTcMrlIrؓǑc9p,I+GG8%O&o|o
{#ΜSGI]ni=wc mњ?g1MEg:
8m`vA!%_̕r̭r=sRm4
INC)*f!!x!EV0JwK(9rKIƳQ 40-f>
`E
Bs1Vj_H҄50o0
r`/סs43&BPEz`tKAbDCC*
ѰVhٸ DW4̾jH+L0"&pYxN}R-
̃uZGS:eV2+gW//HxSeN??N܈P1\ $ ccX:y`
>ຂ=^So]ձŕc*xXp" U,8bI(
ˢbYP,*/}+Tu+Tu+Tu:%vwwBc:[9ت3ՎꜰSY_dKg.gf$˾suxm|)Rܶ6mX?o.;!Z0lF}7}{Cp^G=\Op=OawNvm.Fw89av86aۅS9x=6J/$OR_t#`8ZW]~{0L@jF{U3ͨQ
&]2(|x^}H{\ >;6s榘>KyV!zKzih+ցgs}s+9=
endstream
endobj
282 0 obj
<< /Type /ObjStm /Length 980 /Filter /FlateDecode /N 100 /First 873 >>
stream
xWn9z" H]ܕA )S3^g]VF$֥kʩtKVxKMkK[4FNZ6%pɜ{K}MNRU{ZiIsNp_Rk{KùGx{ėDyRIJGF +Ga8=x3d#`6C+0;
BZmWz<2=`JGe\Y J4G9UJuh,vČcfsPEj`F̕)溁ܔ[#;Jξ`.lz6QJLQKN訟:K\ybV>Se2%
etʔ+ GC.[c<@P)J#WB}Ma:;l
}KFcd`f]p%s;1=}Eܺ`DôiLh
ch(w'yf-Y'1{=Ð}O0$cf-a ZH:>'RC
ڞ`HA){!7b>2OlmC1w,ޞ_pۺvc Y>^!#_8+Xr|۾7~n̵k~G.~Aʸzi~E3ۺ8MdL>9Χ}>_5ayKs-a[#s ;u癹[5.bf⻞k +=f endstream
endobj
383 0 obj
<< /Filter /FlateDecode /Length 3596 >>
stream
HWis_1\)QmmYڍUR0